메뉴 건너뛰기




Volumn 10, Issue 1, 2012, Pages 64-110

Chronic myelogenous leukemia

(20)  O'Brien, Susan a   Abboud, Camille N b   Akhtari, Mojtaba c   Altman, Jessica d   Berman, Ellin e   DeAngelo, Daniel J f   Devine, Steven g   Fathi, Amir T h   Gotlib, Jason i   Jagasia, Madan j   Moore, Joseph O k   Pinilla Ibarz, Javier l   Radich, Jerald P m   Reddy, Vishnu V B n   Shah, Neil P o   Shami, Paul J p   Smith, B Douglas q   Snyder, David S r   Wetzler, Meir s   Yunus, Furhan t  


Author keywords

BCR ABL; Chronic myelogenous leukemia; Dasatinib; Imatinib; NCCN clinical practice guidelines; NCCN guidelines; Nilotinib; Stem cell transplant; Tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; DASATINIB; IMATINIB; NILOTINIB;

EID: 84863415772     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0009     Document Type: Review
Times cited : (20)

References (263)
  • 3
    • 33644525274 scopus 로고    scopus 로고
    • Gene expression changes associated with progression and response in chronic myeloid leukemia
    • Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006;103:2794-2799.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 2794-2799
    • Radich, J.P.1    Dai, H.2    Mao, M.3
  • 4
    • 0033614446 scopus 로고    scopus 로고
    • Chronic myeloid leukemia
    • DOI 10.1056/NEJM199904293401706
    • Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-1340. (Pubitemid 29196596)
    • (1999) New England Journal of Medicine , vol.340 , Issue.17 , pp. 1330-1340
    • Sawyers, C.L.1
  • 6
    • 0021336851 scopus 로고
    • Prognostic discrimination in 'good-risk' chronic granulocytic leukemia
    • Sokal J, Cox E, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984;63:789-799. (Pubitemid 14141296)
    • (1984) Blood , vol.63 , Issue.4 , pp. 789-799
    • Sokal, J.E.1    Cox, E.B.2    Baccarani, M.3
  • 8
    • 34249096219 scopus 로고    scopus 로고
    • Current and emerging treatment options in chronic myeloid leukemia
    • DOI 10.1002/cncr.22661
    • Jabbour E, Cortes JE, Giles FJ, et al. Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007;109:2171-2181. (Pubitemid 46801546)
    • (2007) Cancer , vol.109 , Issue.11 , pp. 2171-2181
    • Jabbour, E.1    Cortes, J.E.2    Giles, F.J.3    O'Brien, S.4    Kantarjian, H.M.5
  • 9
    • 2942593704 scopus 로고    scopus 로고
    • Optimizing treatment of chronic myeloid leukemia: A rational approach
    • DOI 10.1634/theoncologist.9-3-259
    • Stone RM. Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist 2004;9:259-270. (Pubitemid 38756875)
    • (2004) Oncologist , vol.9 , Issue.3 , pp. 259-270
    • Stone, R.M.1
  • 14
    • 77949767505 scopus 로고    scopus 로고
    • International randomized study of interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib
    • [abstract]. Abstract 1126
    • Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood 2009;114:Abstract 1126.
    • (2009) Blood , vol.114
    • Deininger, M.1    O'Brien, S.G.2    Guilhot, F.3
  • 16
    • 33748133844 scopus 로고    scopus 로고
    • Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: Historical comparison between two phase 3 trials
    • DOI 10.1182/blood-2006-02-001495
    • Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108:1478-1484. (Pubitemid 44316111)
    • (2006) Blood , vol.108 , Issue.5 , pp. 1478-1484
    • Roy, L.1    Guilhot, J.2    Krahnke, T.3    Guerci-Bresler, A.4    Druker, B.J.5    Larson, R.A.6    O'Brien, S.7    So, C.8    Massimini, G.9    Guilhot, F.10
  • 17
    • 73149122765 scopus 로고    scopus 로고
    • High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: Results from the International Randomized Study of Interferon and STI571 (IRIS) trial
    • Guilhot F, Druker B, Larson RA, et al. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica 2009;94:1669-1675.
    • (2009) Haematologica , vol.94 , pp. 1669-1675
    • Guilhot, F.1    Druker, B.2    Larson, R.A.3
  • 18
    • 34447544253 scopus 로고    scopus 로고
    • BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia
    • DOI 10.1056/NEJMct071828
    • Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007;357:258-265. (Pubitemid 47080390)
    • (2007) New England Journal of Medicine , vol.357 , Issue.3 , pp. 258-265
    • Schiffer, C.A.1
  • 19
    • 33646482407 scopus 로고    scopus 로고
    • Altered bone and mineral metabolism in patients receiving imatinib mesylate
    • Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006-2013.
    • (2006) N Engl J Med , vol.354 , pp. 2006-2013
    • Berman, E.1    Nicolaides, M.2    Maki, R.G.3
  • 20
    • 2642553015 scopus 로고    scopus 로고
    • Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia
    • Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Granulocyte-colony- stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 2004;100:2592-2597.
    • (2004) Cancer , vol.100 , pp. 2592-2597
    • Quintas-Cardama, A.1    Kantarjian, H.2    O'Brien, S.3
  • 21
    • 2442669344 scopus 로고    scopus 로고
    • Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase
    • DOI 10.1002/cncr.20292
    • Cortes J, O'Brien S, Quintas A, et al. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 2004;100:2396-2402. (Pubitemid 38657887)
    • (2004) Cancer , vol.100 , Issue.11 , pp. 2396-2402
    • Cortes, J.1    O'Brien, S.2    Quintas, A.3    Giles, F.4    Shan, J.5    Rios, M.B.6    Talpaz, M.7    Kantarjian, H.8
  • 22
    • 79952009886 scopus 로고    scopus 로고
    • Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib
    • Santos FP, Alvarado Y, Kantarjian H, et al. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 2011;117:982-991.
    • (2011) Cancer , vol.117 , pp. 982-991
    • Santos, F.P.1    Alvarado, Y.2    Kantarjian, H.3
  • 24
    • 34548030470 scopus 로고    scopus 로고
    • Congestive heart failure is a rare event in patients receiving imatinib therapy
    • DOI 10.1182/blood-2007-01-070144
    • Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007;110:1233-1237. (Pubitemid 47281421)
    • (2007) Blood , vol.110 , Issue.4 , pp. 1233-1237
    • Atallah, E.1    Durand, J.-B.2    Kantarjian, H.3    Cortes, J.4
  • 25
    • 58149160055 scopus 로고    scopus 로고
    • Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
    • Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 2008;112:3965-3973.
    • (2008) Blood , vol.112 , pp. 3965-3973
    • Hughes, T.P.1    Branford, S.2    White, D.L.3
  • 27
    • 70350442594 scopus 로고    scopus 로고
    • High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses
    • Cortes JE, Kantarjian HM, Goldberg SL, et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 2009;27:4754-4759.
    • (2009) J Clin Oncol , vol.27 , pp. 4754-4759
    • Cortes, J.E.1    Kantarjian, H.M.2    Goldberg, S.L.3
  • 28
    • 65349140717 scopus 로고    scopus 로고
    • Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: A phase 2 trial of the GIMEMA CML Working Party
    • Castagnetti F, Palandri F, Amabile M, et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood 2009;113:3428-3434.
    • (2009) Blood , vol.113 , pp. 3428-3434
    • Castagnetti, F.1    Palandri, F.2    Amabile, M.3
  • 29
    • 66549108340 scopus 로고    scopus 로고
    • Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: A European LeukemiaNet Study
    • Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia- positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009;113:4497-4504.
    • (2009) Blood , vol.113 , pp. 4497-4504
    • Baccarani, M.1    Rosti, G.2    Castagnetti, F.3
  • 30
    • 75749105885 scopus 로고    scopus 로고
    • Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study
    • Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010;28:424-430.
    • (2010) J Clin Oncol , vol.28 , pp. 424-430
    • Cortes, J.E.1    Baccarani, M.2    Guilhot, F.3
  • 31
    • 79955018499 scopus 로고    scopus 로고
    • Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia
    • Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29:1634-1642.
    • (2011) J Clin Oncol , vol.29 , pp. 1634-1642
    • Hehlmann, R.1    Lauseker, M.2    Jung-Munkwitz, S.3
  • 32
    • 3142676436 scopus 로고    scopus 로고
    • Overriding imatinib resistance with a novel ABL kinase inhibitor
    • DOI 10.1126/science.1099480
    • Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401. (Pubitemid 38938156)
    • (2004) Science , vol.305 , Issue.5682 , pp. 399-401
    • Shah, N.P.1    Tran, C.2    Lee, F.Y.3    Chen, P.4    Norris, D.5    Sawyers, C.L.6
  • 35
    • 54949154484 scopus 로고    scopus 로고
    • Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)
    • [abstract]. Abstract 7009
    • Mauro MJ, Baccarani M, Cervantes F, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract]. J Clin Oncol 2008;26:Abstract 7009.
    • (2008) J Clin Oncol , vol.26
    • Mauro, M.J.1    Baccarani, M.2    Cervantes, F.3
  • 36
    • 68549140912 scopus 로고    scopus 로고
    • Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP)
    • [abstract]. Abstract 450
    • Baccarani M, Rosti G, Saglio G, et al. Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood 2008;112:Abstract 450.
    • (2008) Blood , vol.112
    • Baccarani, M.1    Rosti, G.2    Saglio, G.3
  • 38
    • 70249141675 scopus 로고    scopus 로고
    • Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: The START A trial
    • Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol 2009;27:3472-3479.
    • (2009) J Clin Oncol , vol.27 , pp. 3472-3479
    • Apperley, J.F.1    Cortes, J.E.2    Kim, D.W.3
  • 40
    • 57849159300 scopus 로고    scopus 로고
    • Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
    • Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008;22:2176-2183.
    • (2008) Leukemia , vol.22 , pp. 2176-2183
    • Cortes, J.1    Kim, D.W.2    Raffoux, E.3
  • 41
    • 67651089848 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
    • Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114:261-263.
    • (2009) Blood , vol.114 , pp. 261-263
    • Quintas-Cardama, A.1    Han, X.2    Kantarjian, H.3    Cortes, J.4
  • 43
    • 68749108104 scopus 로고    scopus 로고
    • Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
    • Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-1405.
    • (2009) Leukemia , vol.23 , pp. 1398-1405
    • Mustjoki, S.1    Ekblom, M.2    Arstila, T.P.3
  • 44
    • 75649105405 scopus 로고    scopus 로고
    • Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion
    • Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116:377-386.
    • (2010) Cancer , vol.116 , pp. 377-386
    • Porkka, K.1    Khoury, H.J.2    Paquette, R.L.3
  • 45
    • 79952788297 scopus 로고    scopus 로고
    • Association of lymphocytosis following treatment with dasatinib with response and outcome
    • [abstract]. Abstract 6553
    • Schiffer CA, Cortes JE, Saglio G, et al. Association of lymphocytosis following treatment with dasatinib with response and outcome [abstract]. J Clin Oncol 2010;28:Abstract 6553.
    • (2010) J Clin Oncol , vol.28
    • Schiffer, C.A.1    Cortes, J.E.2    Saglio, G.3
  • 46
    • 79952780448 scopus 로고    scopus 로고
    • Lymphocytosis following first-line treatment for CML in chronic phase with dasatinib is associated with improved responses: A comparison with imatinib
    • [abstract]. Abstract 358
    • Schiffer CA, Cortes JE, Saglio G, et al. Lymphocytosis following first-line treatment for CML in chronic phase with dasatinib is associated with improved responses: a comparison with imatinib [abstract]. Blood 2010;116:Abstract 358.
    • (2010) Blood , vol.116
    • Schiffer, C.A.1    Cortes, J.E.2    Saglio, G.3
  • 47
    • 49249121723 scopus 로고    scopus 로고
    • Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
    • Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-3212.
    • (2008) J Clin Oncol , vol.26 , pp. 3204-3212
    • Shah, N.P.1    Kantarjian, H.M.2    Kim, D.W.3
  • 48
    • 76549116248 scopus 로고    scopus 로고
    • Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
    • Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232-240.
    • (2010) Haematologica , vol.95 , pp. 232-240
    • Shah, N.P.1    Kim, D.W.2    Kantarjian, H.3
  • 49
    • 83655161037 scopus 로고    scopus 로고
    • Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib
    • [abstract]. Abstract 6512
    • Shah NP, Cortes JE, Schiffer CA, et al. Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib [abstract]. J Clin Oncol 2011;29 (Suppl 15):Abstract 6512.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL. 15
    • Shah, N.P.1    Cortes, J.E.2    Schiffer, C.A.3
  • 50
    • 67650607999 scopus 로고    scopus 로고
    • Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-Month median follow-up
    • Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113:6322-6329.
    • (2009) Blood , vol.113 , pp. 6322-6329
    • Kantarjian, H.1    Cortes, J.2    Kim, D.W.3
  • 51
    • 77956823937 scopus 로고    scopus 로고
    • Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: Efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily
    • Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer 2010;116:3852-3861.
    • (2010) Cancer , vol.116 , pp. 3852-3861
    • Saglio, G.1    Hochhaus, A.2    Goh, Y.T.3
  • 52
    • 75749129911 scopus 로고    scopus 로고
    • Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia
    • Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28:398-404.
    • (2010) J Clin Oncol , vol.28 , pp. 398-404
    • Cortes, J.E.1    Jones, D.2    O'Brien, S.3
  • 53
    • 77953725855 scopus 로고    scopus 로고
    • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
    • Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-2270.
    • (2010) N Engl J Med , vol.362 , pp. 2260-2270
    • Kantarjian, H.1    Shah, N.P.2    Hochhaus, A.3
  • 54
    • 83655174011 scopus 로고    scopus 로고
    • Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION
    • [abstract]. Abstract 6510
    • Kantarjian H, Shah NP, Cortes JE, et al. Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): two-year follow-up from DASISION [abstract]. J Clin Oncol 2011;29 (Suppl 15):Abstract 6510.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL. 15
    • Kantarjian, H.1    Shah, N.P.2    Cortes, J.E.3
  • 55
    • 79952787880 scopus 로고    scopus 로고
    • A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): The S0325 Intergroup trial
    • [abstract]. Abstract LBA-6
    • Radich JP, Kopecky KJ, Kamel-Reid S, et al. A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 Intergroup trial [abstract]. Blood 2010;116:Abstract LBA-6.
    • (2010) Blood , vol.116
    • Radich, J.P.1    Kopecky, K.J.2    Kamel-Reid, S.3
  • 58
    • 79251546724 scopus 로고    scopus 로고
    • Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-Month follow-up results
    • Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117:1141-1145.
    • (2011) Blood , vol.117 , pp. 1141-1145
    • Kantarjian, H.M.1    Giles, F.J.2    Bhalla, K.N.3
  • 60
    • 72149111552 scopus 로고    scopus 로고
    • Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
    • [abstract]. Abstract 7057
    • le Coutre PD, Giles F, Hochhaus A, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study [abstract]. J Clin Oncol 2009;27 (Suppl 15):Abstract 7057.
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL. 15
    • Le Coutre, P.D.1    Giles, F.2    Hochhaus, A.3
  • 61
    • 78649244836 scopus 로고    scopus 로고
    • Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib
    • [abstract]. Abstract 6510
    • Giles FJ, Kantarjian H, le Coutre PD, et al. Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib [abstract]. J Clin Oncol 2010;28 (Suppl 15):Abstract 6510.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. 15
    • Giles, F.J.1    Kantarjian, H.2    Le Coutre, P.D.3
  • 62
    • 75749090051 scopus 로고    scopus 로고
    • Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase
    • Cortes JE, Jones D, O'Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010;28:392-397.
    • (2010) J Clin Oncol , vol.28 , pp. 392-397
    • Cortes, J.E.1    Jones, D.2    O'Brien, S.3
  • 63
    • 73949145209 scopus 로고    scopus 로고
    • Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
    • Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood 2009;114:4933-4938.
    • (2009) Blood , vol.114 , pp. 4933-4938
    • Rosti, G.1    Palandri, F.2    Castagnetti, F.3
  • 64
    • 77953691179 scopus 로고    scopus 로고
    • Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
    • Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.
    • (2010) N Engl J Med , vol.362 , pp. 2251-2259
    • Saglio, G.1    Kim, D.W.2    Issaragrisil, S.3
  • 65
    • 81555217734 scopus 로고    scopus 로고
    • Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up
    • [abstract]. Abstract 6511
    • Larson RA, Kim D, Rosti G, et al. Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up [abstract]. J Clin Oncol 2011;29 (Suppl 15):Abstract 6511.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL. 15
    • Larson, R.A.1    Kim, D.2    Rosti, G.3
  • 66
    • 68149158548 scopus 로고    scopus 로고
    • Imatinib use during pregnancy and breast feeding: A case report and review of the literature
    • Ali R, Ozkalemkas F, Kimya Y, et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet 2009;280:169-175.
    • (2009) Arch Gynecol Obstet , vol.280 , pp. 169-175
    • Ali, R.1    Ozkalemkas, F.2    Kimya, Y.3
  • 70
    • 2342449904 scopus 로고    scopus 로고
    • Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib [2]
    • DOI 10.1080/10428190310001645195
    • Heartin E, Walkinshaw S, Clark RE. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. Leuk Lymphoma 2004;45:1307-1308. (Pubitemid 38584921)
    • (2004) Leukemia and Lymphoma , vol.45 , Issue.6 , pp. 1307-1308
    • Heartin, E.1    Walkinshaw, S.2    Clark, R.E.3
  • 72
    • 47049124097 scopus 로고    scopus 로고
    • The effects of imatinib on pregnancy outcome
    • Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood 2008;111:5505-5508.
    • (2008) Blood , vol.111 , pp. 5505-5508
    • Pye, S.M.1    Cortes, J.2    Ault, P.3
  • 73
    • 34247524263 scopus 로고    scopus 로고
    • Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy [1]
    • DOI 10.1111/j.1365-2141.2007.06542.x
    • Ramasamy K, Hayden J, Lim Z, et al. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol 2007;137:374-375. (Pubitemid 46650245)
    • (2007) British Journal of Haematology , vol.137 , Issue.4 , pp. 374-375
    • Ramasamy, K.1    Hayden, J.2    Lim, Z.3    Mufti, G.J.4    Ho, A.Y.L.5
  • 74
    • 72149123050 scopus 로고    scopus 로고
    • Two year data from a prospective safety study analyzing the consequences of imatinib mesylate inhibition of sensitive kinases other than bcr-abl in patients with previously untreated chronic phase CML
    • [abstract]. Abstract 2147
    • Seymour JF, Grigg A, Reynolds J, et al. Two year data from a prospective safety study analyzing the consequences of imatinib mesylate inhibition of sensitive kinases other than bcr-abl in patients with previously untreated chronic phase CML [abstract]. Blood 2006;108:Abstract 2147.
    • (2006) Blood , vol.108
    • Seymour, J.F.1    Grigg, A.2    Reynolds, J.3
  • 75
    • 67749104495 scopus 로고    scopus 로고
    • Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib
    • [abstract]. Abstract 3230
    • Cortes J, O'Brien S, Ault P, et al. Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib [abstract]. Blood 2008;112:Abstract 3230.
    • (2008) Blood , vol.112
    • Cortes, J.1    O'Brien, S.2    Ault, P.3
  • 76
    • 77954607268 scopus 로고    scopus 로고
    • Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy
    • Conchon M, Sanabani SS, Serpa M, et al. Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol 2010;2010:136252.
    • (2010) Adv Hematol , vol.2010 , pp. 136252
    • Conchon, M.1    Sanabani, S.S.2    Serpa, M.3
  • 77
    • 78751591628 scopus 로고    scopus 로고
    • Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib
    • [published online ahead of print May 15, 2010]
    • Oweini H, Otrock ZK, Mahfouz RAR, Bazarbachi A. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib [published online ahead of print May 15, 2010]. Arch Gynecol Obstet 2011;283:133-134.
    • (2011) Arch Gynecol Obstet , vol.283 , pp. 133-134
    • Oweini, H.1    Otrock, Z.K.2    Mahfouz, R.A.R.3    Bazarbachi, A.4
  • 78
    • 70350365851 scopus 로고    scopus 로고
    • Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: Case study
    • Conchon M, Sanabani SS, Bendit I, et al. Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol 2009;2:42.
    • (2009) J Hematol Oncol , vol.2 , pp. 42
    • Conchon, M.1    Sanabani, S.S.2    Bendit, I.3
  • 79
    • 0038518619 scopus 로고    scopus 로고
    • Practical management of patients with chronic myeloid leukemia receiving imatinib
    • DOI 10.1200/JCO.2003.11.143
    • Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-1647. (Pubitemid 46594119)
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.8 , pp. 1637-1647
    • Deininger, M.W.N.1    O'Brien, S.G.2    Ford, J.M.3    Druker, B.J.4
  • 80
    • 0025866840 scopus 로고
    • Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients
    • Guo JQ, Wang JYJ, Arlinghaus RB. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Research 1991;51:3048-3051.
    • (1991) Cancer Research , vol.51 , pp. 3048-3051
    • Guo, J.Q.1    Wang, J.Y.J.2    Arlinghaus, R.B.3
  • 81
    • 0028835396 scopus 로고
    • Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results
    • Cortes JE, Talpaz M, Beran M, et al. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer 1995;75:464-470.
    • (1995) Cancer , vol.75 , pp. 464-470
    • Cortes, J.E.1    Talpaz, M.2    Beran, M.3
  • 82
    • 79952791065 scopus 로고    scopus 로고
    • NCCN Task Force report: Tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia
    • O'Brien S, Berman E, Moore JO, et al. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw 2011;9 (Suppl 2):S1-S25.
    • (2011) J Natl Compr Canc Netw , vol.9 , Issue.SUPPL. 2
    • O'Brien, S.1    Berman, E.2    Moore, J.O.3
  • 83
    • 33947628168 scopus 로고    scopus 로고
    • Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia
    • DOI 10.1080/10428190601175393, PII 773533619
    • Lipton JH, Khoroshko N, Golenkov A, et al. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma 2007;48:497-505. (Pubitemid 46487756)
    • (2007) Leukemia and Lymphoma , vol.48 , Issue.3 , pp. 497-505
    • Lipton, J.H.1    Khoroshko, N.2    Golenkov, A.3    Abdulkadyrov, K.4    Nair, K.5    Raghunadharao, D.6    Brummendorf, T.7    Yoo, K.8    Bergstrom, B.9
  • 86
    • 43249083718 scopus 로고    scopus 로고
    • Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study
    • Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022-4028.
    • (2008) Blood , vol.111 , pp. 4022-4028
    • Larson, R.A.1    Druker, B.J.2    Guilhot, F.3
  • 88
    • 68549108595 scopus 로고    scopus 로고
    • Clinical use of imatinib plasma levels in patients with chronic myeloid leukemia (CML)
    • [abstract]. Abstract 4255
    • Ault P, Kantarjian HM, Bryan J, et al. Clinical use of imatinib plasma levels in patients with chronic myeloid leukemia (CML) [abstract]. Blood 2008;112:Abstract 4255.
    • (2008) Blood , vol.112
    • Ault, P.1    Kantarjian, H.M.2    Bryan, J.3
  • 89
    • 57049115901 scopus 로고    scopus 로고
    • Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels
    • Forrest DL, Trainor S, Brinkman RR, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 2009;33:271-275.
    • (2009) Leuk Res , vol.33 , pp. 271-275
    • Forrest, D.L.1    Trainor, S.2    Brinkman, R.R.3
  • 90
    • 9444282642 scopus 로고    scopus 로고
    • Active transport of imatinib into and out of cells: Implications for drug resistance
    • DOI 10.1182/blood-2003-12-4276
    • Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-3745. (Pubitemid 39564452)
    • (2004) Blood , vol.104 , Issue.12 , pp. 3739-3745
    • Thomas, J.1    Wang, L.2    Clark, R.E.3    Pirmohamed, M.4
  • 91
    • 38349193809 scopus 로고    scopus 로고
    • Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia
    • Wang L, Giannoudis A, Lane S, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008;83:258-264.
    • (2008) Clin Pharmacol Ther , vol.83 , pp. 258-264
    • Wang, L.1    Giannoudis, A.2    Lane, S.3
  • 92
    • 37049028176 scopus 로고    scopus 로고
    • Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity
    • DOI 10.1182/blood-2007-06-093617
    • White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007;110:4064-4072. (Pubitemid 350248463)
    • (2007) Blood , vol.110 , Issue.12 , pp. 4064-4072
    • White, D.L.1    Saunders, V.A.2    Dang, P.3    Engler, J.4    Venables, A.5    Zrim, S.6    Zannettino, A.7    Lynch, K.8    Manley, P.W.9    Hughes, T.10
  • 93
    • 77954936879 scopus 로고    scopus 로고
    • Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib
    • White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010;28:2761-2767.
    • (2010) J Clin Oncol , vol.28 , pp. 2761-2767
    • White, D.L.1    Dang, P.2    Engler, J.3
  • 94
    • 54049128527 scopus 로고    scopus 로고
    • Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): Implications for the treatment of imatinib-resistant chronic myeloid leukemia
    • Giannoudis A, Davies A, Lucas CM, et al. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008;112:3348-3354.
    • (2008) Blood , vol.112 , pp. 3348-3354
    • Giannoudis, A.1    Davies, A.2    Lucas, C.M.3
  • 95
    • 52449100460 scopus 로고    scopus 로고
    • Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications
    • Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008;14:3881-3888.
    • (2008) Clin Cancer Res , vol.14 , pp. 3881-3888
    • Hiwase, D.K.1    Saunders, V.2    Hewett, D.3
  • 96
    • 70450255111 scopus 로고    scopus 로고
    • Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
    • Davies A, Jordanides NE, Giannoudis A, et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009;23:1999-2006.
    • (2009) Leukemia , vol.23 , pp. 1999-2006
    • Davies, A.1    Jordanides, N.E.2    Giannoudis, A.3
  • 97
    • 33745085275 scopus 로고    scopus 로고
    • OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
    • DOI 10.1182/blood-2005-11-4687
    • White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697-704. (Pubitemid 44061372)
    • (2006) Blood , vol.108 , Issue.2 , pp. 697-704
    • White, D.L.1    Saunders, V.A.2    Dang, P.3    Engler, J.4    Zannettino, A.C.W.5    Cambareri, A.C.6    Quinn, S.R.7    Manley, P.W.8    Hughes, T.P.9
  • 98
    • 0035800507 scopus 로고    scopus 로고
    • Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
    • DOI 10.1126/science.1062538
    • Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880. (Pubitemid 32743979)
    • (2001) Science , vol.293 , Issue.5531 , pp. 876-880
    • Gorre, M.E.1    Mohammed, M.2    Ellwood, K.3    Hsu, N.4    Paquette, R.5    Nagesh, R.P.6    Sawyers, C.L.7
  • 101
    • 35448967331 scopus 로고    scopus 로고
    • Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
    • DOI 10.1016/S1470-2045(07)70342-X, PII S147020450770342X
    • Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-1029. (Pubitemid 47629897)
    • (2007) Lancet Oncology , vol.8 , Issue.11 , pp. 1018-1029
    • Apperley, J.F.1
  • 102
    • 54349089682 scopus 로고    scopus 로고
    • Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression
    • Khorashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008;26:4806-4813.
    • (2008) J Clin Oncol , vol.26 , pp. 4806-4813
    • Khorashad, J.S.1    De Lavallade, H.2    Apperley, J.F.3
  • 103
    • 10744232328 scopus 로고    scopus 로고
    • Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
    • DOI 10.1182/blood-2002-09-2896
    • Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-283. (Pubitemid 36759665)
    • (2003) Blood , vol.102 , Issue.1 , pp. 276-283
    • Branford, S.1    Rudzki, Z.2    Walsh, S.3    Parkinson, I.4    Grigg, A.5    Szer, J.6    Taylor, K.7    Herrmann, R.8    Seymour, J.F.9    Arthur, C.10    Joske, D.11    Lynch, K.12    Hughes, T.13
  • 108
    • 47249123747 scopus 로고    scopus 로고
    • Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
    • Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008;112:53-55.
    • (2008) Blood , vol.112 , pp. 53-55
    • Jabbour, E.1    Kantarjian, H.2    Jones, D.3
  • 111
    • 0942287753 scopus 로고    scopus 로고
    • Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate
    • DOI 10.1182/blood-2003-02-0371
    • O'Dwyer ME, Mauro MJ, Blasdel C, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004;103:451-455. (Pubitemid 38140072)
    • (2004) Blood , vol.103 , Issue.2 , pp. 451-455
    • O'Dwyer, M.E.1    Mauro, M.J.2    Blasdel, C.3    Farnsworth, M.4    Kurilik, G.5    Hsieh, Y.-C.6    Mori, M.7    Druker, B.J.8
  • 114
    • 77952845388 scopus 로고    scopus 로고
    • Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy
    • Verma D, Kantarjian H, Shan J, et al. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 2010;116:2673-2681.
    • (2010) Cancer , vol.116 , pp. 2673-2681
    • Verma, D.1    Kantarjian, H.2    Shan, J.3
  • 116
    • 0141705292 scopus 로고    scopus 로고
    • Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses [7] (multiple letters)
    • DOI 10.1182/blood-2003-06-2042
    • Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 2003;102:2702-2704. (Pubitemid 37193621)
    • (2003) Blood , vol.102 , Issue.7 , pp. 2702-2704
    • Marin, D.1    Goldman, J.M.2    Olavarria, E.3    Apperley, J.F.4    Cortes, J.5    Kantarjian, H.6
  • 117
    • 0038176390 scopus 로고    scopus 로고
    • The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment
    • Zonder JA, Pemberton P, Brandt H, et al. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003;9:2092-2097. (Pubitemid 36687630)
    • (2003) Clinical Cancer Research , vol.9 , Issue.6 , pp. 2092-2097
    • Zonder, J.A.1    Pemberton, P.2    Brandt, H.3    Mohamed, A.N.4    Schiffer, C.A.5
  • 118
    • 64049099666 scopus 로고    scopus 로고
    • Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
    • Jabbour E, Kantarjian HM, Jones D, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009;113:2154-2160.
    • (2009) Blood , vol.113 , pp. 2154-2160
    • Jabbour, E.1    Kantarjian, H.M.2    Jones, D.3
  • 119
    • 60049092698 scopus 로고    scopus 로고
    • Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase
    • Kantarjian HM, Larson RA, Guilhot F, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009;115:551-560.
    • (2009) Cancer , vol.115 , pp. 551-560
    • Kantarjian, H.M.1    Larson, R.A.2    Guilhot, F.3
  • 121
    • 70149105272 scopus 로고    scopus 로고
    • Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R)
    • Kantarjian H, Pasquini R, Levy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115:4136-4147.
    • (2009) Cancer , vol.115 , pp. 4136-4147
    • Kantarjian, H.1    Pasquini, R.2    Levy, V.3
  • 122
    • 51649120694 scopus 로고    scopus 로고
    • Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia
    • Quintas-Cardama A, Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 2008;14:4392-4399.
    • (2008) Clin Cancer Res , vol.14 , pp. 4392-4399
    • Quintas-Cardama, A.1    Cortes, J.2
  • 123
    • 17644395643 scopus 로고    scopus 로고
    • Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
    • DOI 10.1002/cncr.20975
    • Marin D, Kaeda JS, Andreasson C, et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005;103:1850-1855. (Pubitemid 40563257)
    • (2005) Cancer , vol.103 , Issue.9 , pp. 1850-1855
    • Marin, D.1    Kaeda, J.S.2    Andreasson, C.3    Saunders, S.M.4    Bua, M.5    Olavarria, E.6    Goldman, J.M.7    Apperley, J.F.8
  • 125
    • 72149093397 scopus 로고    scopus 로고
    • Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial
    • [abstract]. Abstract 7008
    • Cortes JE, Khoury HJ, Corm S, et al. Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: data from an ongoing phase II/III trial [abstract]. J Clin Oncol 2009;27 (Suppl 15):Abstract 7008.
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL. 15
    • Cortes, J.E.1    Khoury, H.J.2    Corm, S.3
  • 126
    • 79954529064 scopus 로고    scopus 로고
    • Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial
    • [abstract]. Abstract 7027
    • Wetzler M, Hellmann A, Lipton J, et al. Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): data from an ongoing phase II trial [abstract]. J Clin Oncol 2009;27(Suppl 15):Abstract 7027.
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL. 15
    • Wetzler, M.1    Hellmann, A.2    Lipton, J.3
  • 127
    • 41349123259 scopus 로고    scopus 로고
    • Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: Practical advice on the use and interpretation of monitoring methods
    • DOI 10.1182/blood-2007-09-110189
    • Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008;111:1774-1780. (Pubitemid 351451481)
    • (2008) Blood , vol.111 , Issue.4 , pp. 1774-1780
    • Kantarjian, H.1    Schiffer, C.2    Jones, D.3    Cortes, J.4
  • 128
    • 77949442316 scopus 로고    scopus 로고
    • Monitoring disease response to tyrosine kinase inhibitor therapy in CML
    • Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematology Am Soc Hematol Educ Program 2009:477-487.
    • (2009) Hematology Am Soc Hematol Educ Program , pp. 477-487
    • Hughes, T.P.1    Branford, S.2
  • 129
    • 70350717760 scopus 로고    scopus 로고
    • How I monitor residual disease in chronic myeloid leukemia
    • Radich JP. How I monitor residual disease in chronic myeloid leukemia. Blood 2009;114:3376-3381.
    • (2009) Blood , vol.114 , pp. 3376-3381
    • Radich, J.P.1
  • 130
    • 33750469708 scopus 로고    scopus 로고
    • Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia
    • DOI 10.1080/10428190600783551, PII R520U181V137218V
    • Landstrom AP, Ketterling RP, Knudson RA, Tefferi A. Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. Leuk Lymphoma 2006;47:2055-2061. (Pubitemid 44650080)
    • (2006) Leukemia and Lymphoma , vol.47 , Issue.10 , pp. 2055-2061
    • Landstrom, A.P.1    Ketterling, R.P.2    Knudson, R.A.3    Tefferi, A.4
  • 131
    • 0345487506 scopus 로고    scopus 로고
    • Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: A new strategy for remission assessment
    • DOI 10.1002/(SICI)1098-2264(199802)21:2<90::AID-GCC3>3.0.CO;2-2
    • Muhlmann J, Thaler J, Hilbe W, et al. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer 1998;21:90-100. (Pubitemid 28081234)
    • (1998) Genes Chromosomes and Cancer , vol.21 , Issue.2 , pp. 90-100
    • Muhlmann, J.1    Thaler, J.2    Hilbe, W.3    Bechter, O.4    Erdel, M.5    Utermann, G.6    Duba, H.-C.7
  • 133
    • 0029098199 scopus 로고
    • Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment
    • Seong DC, Kantarjian HM, Ro JY, et al. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 1995;86:2343-2349.
    • (1995) Blood , vol.86 , pp. 2343-2349
    • Seong, D.C.1    Kantarjian, H.M.2    Ro, J.Y.3
  • 134
    • 0032079490 scopus 로고    scopus 로고
    • Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia
    • Dewald GW, Wyatt WA, Juneau AL, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998;91:3357-3365. (Pubitemid 28193887)
    • (1998) Blood , vol.91 , Issue.9 , pp. 3357-3365
    • Dewald, G.W.1    Wyatt, W.A.2    Juneau, A.L.3    Carlson, R.O.4    Zinsmeister, A.R.5    Jalal, S.M.6    Spurbeck, J.L.7    Silver, R.T.8
  • 135
    • 49149111543 scopus 로고    scopus 로고
    • Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis
    • de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-3363.
    • (2008) J Clin Oncol , vol.26 , pp. 3358-3363
    • De Lavallade, H.1    Apperley, J.F.2    Khorashad, J.S.3
  • 136
    • 67649624660 scopus 로고    scopus 로고
    • Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia
    • Quintas-Cardama A, Cortes JE, O'Brien S, et al. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 2009;115:2912-2921.
    • (2009) Cancer , vol.115 , pp. 2912-2921
    • Quintas-Cardama, A.1    Cortes, J.E.2    O'Brien, S.3
  • 137
    • 81155133830 scopus 로고    scopus 로고
    • The achievement of an early complete cytogenetic response (CCyR) is a major determinant for outcome in patients (pts) with early chronic phase (CP) chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs)
    • [abstract]. Abstract 3429
    • Jabbour E, Kantarjian HM, Shan J, et al. The achievement of an early complete cytogenetic response (CCyR) is a major determinant for outcome in patients (pts) with early chronic phase (CP) chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) [abstract]. Blood 2010;116:Abstract 3429.
    • (2010) Blood , vol.116
    • Jabbour, E.1    Kantarjian, H.M.2    Shan, J.3
  • 139
    • 0042167270 scopus 로고    scopus 로고
    • + cells in patients with chronic myeloid leukemia treated with imatinib mesylate
    • DOI 10.1016/S0301-472X(03)00176-0
    • Feldman E, Najfeld V, Schuster M, et al. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol 2003;31:702-707. (Pubitemid 36945383)
    • (2003) Experimental Hematology , vol.31 , Issue.8 , pp. 702-707
    • Feldman, E.1    Najfeld, V.2    Schuster, M.3    Roboz, G.4    Chadburn, A.5    Silver, R.T.6
  • 140
    • 0142243204 scopus 로고    scopus 로고
    • Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Imatinib Mesylate Therapy in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase
    • DOI 10.1002/cncr.11729
    • Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003;98:1905-1911. (Pubitemid 37310233)
    • (2003) Cancer , vol.98 , Issue.9 , pp. 1905-1911
    • Medina, J.1    Kantarjian, H.2    Talpaz, M.3    O'Brien, S.4    Garcia-Manero, G.5    Giles, F.6    Rios, M.B.7    Hayes, K.8    Cortes, J.9
  • 143
    • 35548971639 scopus 로고    scopus 로고
    • Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
    • DOI 10.1182/blood-2007-01-070045
    • Jabbour E, Kantarjian HM, Abruzzo LV, et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007;110:2991-2995. (Pubitemid 350006953)
    • (2007) Blood , vol.110 , Issue.8 , pp. 2991-2995
    • Jabbour, E.1    Kantarjian, H.M.2    Abruzzo, L.V.3    O'Brien, S.4    Garcia-Manero, G.5    Verstovsek, S.6    Shan, J.7    Rios, M.B.8    Cortes, J.9
  • 145
    • 73349122639 scopus 로고    scopus 로고
    • Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet
    • Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-6051.
    • (2009) J Clin Oncol , vol.27 , pp. 6041-6051
    • Baccarani, M.1    Cortes, J.2    Pane, F.3
  • 146
    • 71849110507 scopus 로고    scopus 로고
    • Standardisation of molecular monitoring for chronic myeloid leukaemia
    • Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22:355-365.
    • (2009) Best Pract Res Clin Haematol , vol.22 , pp. 355-365
    • Cross, N.C.1
  • 147
    • 33750327903 scopus 로고    scopus 로고
    • Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia
    • DOI 10.1038/sj.leu.2404388, PII 2404388
    • Branford S, Cross NCP, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006;20:1925-1930. (Pubitemid 44614879)
    • (2006) Leukemia , vol.20 , Issue.11 , pp. 1925-1930
    • Branford, S.1    Cross, N.C.P.2    Hochhaus, A.3    Radich, J.4    Saglio, G.5    Kaeda, J.6    Goldman, J.7    Hughes, T.8
  • 150
    • 33744463354 scopus 로고    scopus 로고
    • BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML
    • DOI 10.1182/blood-2005-11-4406
    • Press RD, Love Z, Tronnes AA, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 2006;107:4250-4256. (Pubitemid 43801348)
    • (2006) Blood , vol.107 , Issue.11 , pp. 4250-4256
    • Press, R.D.1    Love, Z.2    Tronnes, A.A.3    Yang, R.4    Tran, T.5    Mongoue-Tchokote, S.6    Mori, M.7    Mauro, M.J.8    Deininger, M.W.9    Druker, B.J.10
  • 151
    • 35948937212 scopus 로고    scopus 로고
    • A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response
    • DOI 10.1158/1078-0432.CCR-07-1112
    • Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007;13:6136-6143. (Pubitemid 350075073)
    • (2007) Clinical Cancer Research , vol.13 , Issue.20 , pp. 6136-6143
    • Press, R.D.1    Galderisi, C.2    Yang, R.3    Rempfer, C.4    Willis, S.G.5    Mauro, M.J.6    Druker, B.J.7    Deininger, M.W.N.8
  • 152
    • 77958595179 scopus 로고    scopus 로고
    • Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS)
    • Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116:3758-3765.
    • (2010) Blood , vol.116 , pp. 3758-3765
    • Hughes, T.P.1    Hochhaus, A.2    Branford, S.3
  • 155
    • 61349154989 scopus 로고    scopus 로고
    • Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: Importance of a stable molecular response
    • Palandri F, Iacobucci I, Soverini S, et al. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. Clin Cancer Res 2009;15:1059-1063.
    • (2009) Clin Cancer Res , vol.15 , pp. 1059-1063
    • Palandri, F.1    Iacobucci, I.2    Soverini, S.3
  • 156
    • 58149396984 scopus 로고    scopus 로고
    • European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
    • Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008;112:4437-4444.
    • (2008) Blood , vol.112 , pp. 4437-4444
    • Marin, D.1    Milojkovic, D.2    Olavarria, E.3
  • 157
    • 77956034332 scopus 로고    scopus 로고
    • Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: A study of the Spanish PETHEMA group
    • Cervantes F, López-Garrido P, Montero MI, et al. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica 2010;95:1317-1324.
    • (2010) Haematologica , vol.95 , pp. 1317-1324
    • Cervantes, F.1    López-Garrido, P.2    Montero, M.I.3
  • 158
    • 79954986886 scopus 로고    scopus 로고
    • Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy
    • Kantarjian H, Cortes J. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:1512-1516.
    • (2011) J Clin Oncol , vol.29 , pp. 1512-1516
    • Kantarjian, H.1    Cortes, J.2
  • 160
    • 33644516935 scopus 로고    scopus 로고
    • The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia
    • Wang L, Knight K, Lucas C, Clark R. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 2006;91:235-239.
    • (2006) Haematologica , vol.91 , pp. 235-239
    • Wang, L.1    Knight, K.2    Lucas, C.3    Clark, R.4
  • 161
    • 68549095201 scopus 로고    scopus 로고
    • Significance of rising levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in complete cytogenetic response (CGCR)
    • [abstract]. Abstract 445
    • Kantarjian HM, Shan J, Jones D, et al. Significance of rising levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in complete cytogenetic response (CGCR) [abstract]. Blood 2008;112:Abstract 445.
    • (2008) Blood , vol.112
    • Kantarjian, H.M.1    Shan, J.2    Jones, D.3
  • 162
    • 70350509806 scopus 로고    scopus 로고
    • Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib
    • Press RD, Willis SG, Laudadio J, et al. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 2009;114:2598-2605.
    • (2009) Blood , vol.114 , pp. 2598-2605
    • Press, R.D.1    Willis, S.G.2    Laudadio, J.3
  • 163
    • 68949108481 scopus 로고    scopus 로고
    • Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response
    • Kantarjian HM, Shan J, Jones D, et al. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 2009;27:3659-3663.
    • (2009) J Clin Oncol , vol.27 , pp. 3659-3663
    • Kantarjian, H.M.1    Shan, J.2    Jones, D.3
  • 164
    • 76249090055 scopus 로고    scopus 로고
    • Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: Does the BCR-ABL mutation status really matter?
    • Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 2009;114:5426-5435.
    • (2009) Blood , vol.114 , pp. 5426-5435
    • Branford, S.1    Melo, J.V.2    Hughes, T.P.3
  • 165
    • 79955400117 scopus 로고    scopus 로고
    • Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
    • Jabbour E, Branford S, Saglio G, et al. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2011;117:1800-1811.
    • (2011) Cancer , vol.117 , pp. 1800-1811
    • Jabbour, E.1    Branford, S.2    Saglio, G.3
  • 166
    • 73949105873 scopus 로고    scopus 로고
    • Dasatinib treatment of chronic-phase chronic myeloid leukemia: Analysis of responses according to preexisting BCR-ABL mutations
    • Muller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009;114:4944-4953.
    • (2009) Blood , vol.114 , pp. 4944-4953
    • Muller, M.C.1    Cortes, J.E.2    Kim, D.W.3
  • 167
    • 58149380741 scopus 로고    scopus 로고
    • Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
    • Jabbour E, Kantarjian HM, Jones D, et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 2008;112:4839-4842.
    • (2008) Blood , vol.112 , pp. 4839-4842
    • Jabbour, E.1    Kantarjian, H.M.2    Jones, D.3
  • 169
    • 70249105789 scopus 로고    scopus 로고
    • Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase
    • Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27:4204-4210.
    • (2009) J Clin Oncol , vol.27 , pp. 4204-4210
    • Hughes, T.1    Saglio, G.2    Branford, S.3
  • 170
    • 70349254450 scopus 로고    scopus 로고
    • Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
    • Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009;114:2168-2171.
    • (2009) Blood , vol.114 , pp. 2168-2171
    • Soverini, S.1    Gnani, A.2    Colarossi, S.3
  • 171
    • 73949153481 scopus 로고    scopus 로고
    • Chronic myeloid leukemia: A prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: A study of the GIMEMA CML WP
    • Testoni N, Marzocchi G, Luatti S, et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 2009;114:4939-4943.
    • (2009) Blood , vol.114 , pp. 4939-4943
    • Testoni, N.1    Marzocchi, G.2    Luatti, S.3
  • 172
    • 79952375521 scopus 로고    scopus 로고
    • Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond
    • Lima L, Bernal-Mizrachi L, Saxe D, et al. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer 2011;117:1245-1252.
    • (2011) Cancer , vol.117 , pp. 1245-1252
    • Lima, L.1    Bernal-Mizrachi, L.2    Saxe, D.3
  • 173
    • 68549098145 scopus 로고    scopus 로고
    • Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase
    • Alvarado Y, Kantarjian H, O'Brien S, et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009;115:3709-3718.
    • (2009) Cancer , vol.115 , pp. 3709-3718
    • Alvarado, Y.1    Kantarjian, H.2    O'Brien, S.3
  • 174
    • 77951557996 scopus 로고    scopus 로고
    • Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up
    • Breccia M, Stagno F, Vigneri P, et al. Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up. Am J Hematol 2010;85:375-377.
    • (2010) Am J Hematol , vol.85 , pp. 375-377
    • Breccia, M.1    Stagno, F.2    Vigneri, P.3
  • 175
    • 77953072695 scopus 로고    scopus 로고
    • Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib
    • Koh Y, Kim I, Yoon SS, et al. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib. Ann Hematol 2010;89:725-731.
    • (2010) Ann Hematol , vol.89 , pp. 725-731
    • Koh, Y.1    Kim, I.2    Yoon, S.S.3
  • 176
    • 79952037284 scopus 로고    scopus 로고
    • Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: Interim results from the TIDEL-II trial
    • [abstract]. Abstract 209
    • Yeung DT, Osborn M, White DL, et al. Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDEL-II trial [abstract]. Blood 2010;116:Abstract 209.
    • (2010) Blood , vol.116
    • Yeung, D.T.1    Osborn, M.2    White, D.L.3
  • 177
    • 71849094784 scopus 로고    scopus 로고
    • Dasatinib-associated major molecular responses are rapidly achieved in patients with chronic myeloid leukemia in chronic phase (CML-CP) following resistance, suboptimal response, or intolerance on imatinib
    • [abstract]. Abstract 1095
    • Hochhaus A, Muller MC, Radich J, et al. Dasatinib-associated major molecular responses are rapidly achieved in patients with chronic myeloid leukemia in chronic phase (CML-CP) following resistance, suboptimal response, or intolerance on imatinib [abstract]. Blood 2008;112:Abstract 1095.
    • (2008) Blood , vol.112
    • Hochhaus, A.1    Muller, M.C.2    Radich, J.3
  • 178
    • 77955450607 scopus 로고    scopus 로고
    • Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or - intolerant chronic myeloid leukemia (CML) in chronic phase (CP): Sub-analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) study
    • [abstract]. Abstract 2201
    • Nicolini FE, Kim DW, Ceglarek B, et al. Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or - intolerant chronic myeloid leukemia (CML) in chronic phase (CP): sub-analyses of the ENACT (Expanding Nilotinib Access In Clinical Trials) study [abstract]. Blood 2009;114:Abstract 2201.
    • (2009) Blood , vol.114
    • Nicolini, F.E.1    Kim, D.W.2    Ceglarek, B.3
  • 179
    • 78649662408 scopus 로고    scopus 로고
    • Nilotinib-associated molecular responses achieved in chronic myeloid leukemia in chronic phase (CML-CP) patients with a suboptimal molecular response to imatinib
    • [abstract]. Abstract 2206
    • Yang AS, Jillella A, Miller CB, et al. Nilotinib-associated molecular responses achieved in chronic myeloid leukemia in chronic phase (CML-CP) patients with a suboptimal molecular response to imatinib [abstract]. Blood 2009;114:Abstract 2206.
    • (2009) Blood , vol.114
    • Yang, A.S.1    Jillella, A.2    Miller, C.B.3
  • 180
    • 50949119729 scopus 로고    scopus 로고
    • Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
    • Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008;112:516-518.
    • (2008) Blood , vol.112 , pp. 516-518
    • Tam, C.S.1    Kantarjian, H.2    Garcia-Manero, G.3
  • 181
    • 76549114789 scopus 로고    scopus 로고
    • Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
    • Milojkovic D, Nicholson E, Apperley JF, et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2010;95:224-231.
    • (2010) Haematologica , vol.95 , pp. 224-231
    • Milojkovic, D.1    Nicholson, E.2    Apperley, J.F.3
  • 182
    • 79956130861 scopus 로고    scopus 로고
    • Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily
    • [abstract]. Abstract 6512
    • Shah NP, Cortes JE, Schiffer CA, et al. Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily [abstract]. J Clin Oncol 2010;28 (Suppl 15):Abstract 6512.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. 15
    • Shah, N.P.1    Cortes, J.E.2    Schiffer, C.A.3
  • 183
    • 68549138476 scopus 로고    scopus 로고
    • The initial molecular response of chronic phase cml patients treated with second generation ABL inhibitor therapy after imatinib failure can predict inadequate response and provide indications for rational mutation screening
    • [abstract]. Abstract 331
    • Branford S, Lawrence R, Fletcher L, et al. The initial molecular response of chronic phase cml patients treated with second generation ABL inhibitor therapy after imatinib failure can predict inadequate response and provide indications for rational mutation screening [abstract]. Blood 2008;112:Abstract 331.
    • (2008) Blood , vol.112
    • Branford, S.1    Lawrence, R.2    Fletcher, L.3
  • 184
    • 78650495372 scopus 로고    scopus 로고
    • Molecular response at 3 months on nilotinib therapy predicts response and long-term outcomes in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP)
    • [abstract]. Abstract 3292
    • Branford S, Kim DW, Soverini S, et al. Molecular response at 3 months on nilotinib therapy predicts response and long-term outcomes in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood 2009;114:Abstract 3292.
    • (2009) Blood , vol.114
    • Branford, S.1    Kim, D.W.2    Soverini, S.3
  • 185
    • 79951477784 scopus 로고    scopus 로고
    • Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
    • Jabbour E, Kantarjian H, O'Brien S, et al. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood 2011;117:1822-1827.
    • (2011) Blood , vol.117 , pp. 1822-1827
    • Jabbour, E.1    Kantarjian, H.2    O'Brien, S.3
  • 186
    • 73349100015 scopus 로고    scopus 로고
    • The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up
    • Garg RJ, Kantarjian H, O'Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009;114:4361-4368.
    • (2009) Blood , vol.114 , pp. 4361-4368
    • Garg, R.J.1    Kantarjian, H.2    O'Brien, S.3
  • 187
    • 36048979318 scopus 로고    scopus 로고
    • Advances in the treatment of haematological malignancies: Optimal sequence of CML treatment
    • Hochhaus A. Advances in the treatment of haematological malignancies: optimal sequence of CML treatment. Ann Oncol 2007;18 (Suppl 9):ix58-63.
    • (2007) Ann Oncol , vol.18 , Issue.SUPPL. 9
    • Hochhaus, A.1
  • 188
    • 4644341516 scopus 로고    scopus 로고
    • Discontinuation of imatinib therapy after achieving a molecular response [3]
    • DOI 10.1182/blood-2004-04-1335
    • Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004;104:2204-2205. (Pubitemid 39297882)
    • (2004) Blood , vol.104 , Issue.7 , pp. 2204-2205
    • Cortes, J.1    O'Brien, S.2    Kantarjian, H.3
  • 190
    • 77949512757 scopus 로고    scopus 로고
    • The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in cmr, and any relapses occur early
    • [abstract]. Abstract 1102
    • Ross DM, Grigg A, Schwarer A, et al. The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in cmr, and any relapses occur early [abstract]. Blood 2008;112:Abstract 1102.
    • (2008) Blood , vol.112
    • Ross, D.M.1    Grigg, A.2    Schwarer, A.3
  • 191
    • 78049528573 scopus 로고    scopus 로고
    • Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial
    • Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010:1029-1035.
    • (2010) Lancet Oncol , pp. 1029-1035
    • Mahon, F.X.1    Rea, D.2    Guilhot, J.3
  • 192
    • 34249782019 scopus 로고    scopus 로고
    • Treatment interruptions and non-adherence with imatinib and associated healthcare costs: A retrospective analysis among managed care patients with chronic myelogenous leukaemia
    • DOI 10.2165/00019053-200725060-00004
    • Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007;25:481-496. (Pubitemid 46849189)
    • (2007) PharmacoEconomics , vol.25 , Issue.6 , pp. 481-496
    • Darkow, T.1    Henk, H.J.2    Thomas, S.K.3    Feng, W.4    Baladi, J.-F.5    Goldberg, G.A.6    Hatfield, A.7    Cortes, J.8
  • 193
    • 77952467377 scopus 로고    scopus 로고
    • Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
    • Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381-2388.
    • (2010) J Clin Oncol , vol.28 , pp. 2381-2388
    • Marin, D.1    Bazeos, A.2    Mahon, F.X.3
  • 194
    • 67049087117 scopus 로고    scopus 로고
    • Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study
    • Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-5411.
    • (2009) Blood , vol.113 , pp. 5401-5411
    • Noens, L.1    Van Lierde, M.A.2    De Bock, R.3
  • 195
    • 79953823237 scopus 로고    scopus 로고
    • Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
    • Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011;117:3733-3736.
    • (2011) Blood , vol.117 , pp. 3733-3736
    • Ibrahim, A.R.1    Eliasson, L.2    Apperley, J.F.3
  • 198
    • 43749083078 scopus 로고    scopus 로고
    • Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia
    • DOI 10.3816/CLM.2008.s.003
    • Quintas-Cardama A, Cortes JE, Kantarjian H. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma 2008;8 (Suppl 3):S82-S88. (Pubitemid 351692305)
    • (2008) Clinical Lymphoma and Myeloma , vol.8 , Issue.SUPPL. 3
    • Quintas-Cardama, A.1    Cortes, J.E.2    Kantarjian, H.3
  • 200
    • 0030831669 scopus 로고    scopus 로고
    • Bone marrow transplantation for chronic myeloid leukaemia: The effects of differing criteria for defining chronic phase on probabilities of survival and relapse
    • Savage DG, Szydlo RM, Chase A, et al. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol 1997;99:30-35. (Pubitemid 27461323)
    • (1997) British Journal of Haematology , vol.99 , Issue.1 , pp. 30-35
    • Savage, D.G.1    Szydlo, R.M.2    Chase, A.3    Apperley, J.F.4    Goldman, J.M.5
  • 201
    • 0023717986 scopus 로고
    • Staging and prognosis in chronic myelogenous leukemia
    • Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988;25:49-61.
    • (1988) Semin Hematol , vol.25 , pp. 49-61
    • Sokal, J.E.1    Baccarani, M.2    Russo, D.3    Tura, S.4
  • 204
    • 78650713684 scopus 로고    scopus 로고
    • Chronic Myelogenous Leukemia
    • DeVita VT, Lawrence TS, Rosenburg SA, eds. (ed 8): Lippincott, Williams and Wilkins
    • Druker BJ. Chronic Myelogenous Leukemia In: DeVita VT, Lawrence TS, Rosenburg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. Vol. 2(ed 8): Lippincott, Williams and Wilkins; 2007:2267-2304.
    • (2007) DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology , vol.2 , pp. 2267-2304
    • Druker, B.J.1
  • 205
    • 45749097411 scopus 로고    scopus 로고
    • Advanced CML: Therapeutic options for patients in accelerated and blast phases
    • Shah NP. Advanced CML: therapeutic options for patients in accelerated and blast phases. J Natl Compr Canc Netw 2008;6 (Suppl 2):S31-S36. (Pubitemid 351871432)
    • (2008) JNCCN Journal of the National Comprehensive Cancer Network , vol.6 , Issue.SUPPL. 2
    • Shah, N.P.1
  • 207
    • 59549084574 scopus 로고    scopus 로고
    • The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up
    • Palandri F, Castagnetti F, Alimena G, et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica 2009;94:205-212.
    • (2009) Haematologica , vol.94 , pp. 205-212
    • Palandri, F.1    Castagnetti, F.2    Alimena, G.3
  • 210
    • 57349124075 scopus 로고    scopus 로고
    • Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up
    • Palandri F, Castagnetti F, Testoni N, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica 2008;93:1792-1796.
    • (2008) Haematologica , vol.93 , pp. 1792-1796
    • Palandri, F.1    Castagnetti, F.2    Testoni, N.3
  • 211
    • 67149147422 scopus 로고    scopus 로고
    • Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
    • Fava C, Kantarjian HM, Jabbour E, et al. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 2009;113:5058-5063.
    • (2009) Blood , vol.113 , pp. 5058-5063
    • Fava, C.1    Kantarjian, H.M.2    Jabbour, E.3
  • 213
    • 33750470841 scopus 로고    scopus 로고
    • Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: Major challenges in current practice
    • DOI 10.1080/10428190600634085, PII G01G7625254024T1
    • Yanada M, Naoe T. Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice. Leuk Lymphoma 2006;47:1747-1753. (Pubitemid 44649756)
    • (2006) Leukemia and Lymphoma , vol.47 , Issue.9 , pp. 1747-1753
    • Yanada, M.1    Naoe, T.2
  • 215
    • 77956240944 scopus 로고    scopus 로고
    • Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL)
    • [abstract]. Abstract 6506
    • Thomas DA, O'Brien SM, Faderl S, et al. Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) [abstract]. J Clin Oncol 2010;28 (Suppl 15):Abstract 6506.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. 15
    • Thomas, D.A.1    O'Brien, S.M.2    Faderl, S.3
  • 216
    • 77957191745 scopus 로고    scopus 로고
    • First report of phase II study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia
    • Ravandi F, O'Brien S, Thomas D, et al. First report of phase II study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Blood 2010:2070-2077.
    • (2010) Blood , pp. 2070-2077
    • Ravandi, F.1    O'Brien, S.2    Thomas, D.3
  • 217
    • 77957088676 scopus 로고    scopus 로고
    • Stem cell transplant for chronic myeloid leukemia in the imatinib era
    • Radich J. Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin Hematol 2010;47:354-361.
    • (2010) Semin Hematol , vol.47 , pp. 354-361
    • Radich, J.1
  • 218
    • 78751699052 scopus 로고    scopus 로고
    • Three decades of transplantation for chronic myeloid leukemia: What have we learned?
    • Pavlu J, Szydlo RM, Goldman JM, Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 2011;117:755-763.
    • (2011) Blood , vol.117 , pp. 755-763
    • Pavlu, J.1    Szydlo, R.M.2    Goldman, J.M.3    Apperley, J.F.4
  • 219
    • 0035313619 scopus 로고    scopus 로고
    • Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors
    • DOI 10.1016/S0002-9343(01)00629-5, PII S0002934301006295
    • Davies SM, DeFor TE, McGlave PB, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001;110:339-346. (Pubitemid 32245805)
    • (2001) American Journal of Medicine , vol.110 , Issue.5 , pp. 339-346
    • Davies, S.M.1    DeFor, T.E.2    McGlave, P.B.3    Miller, J.S.4    Verfaillie, C.M.5    Wagner, J.E.6    Weisdorf, D.J.7
  • 221
    • 0029952614 scopus 로고    scopus 로고
    • Allogeneic bone marrow transplantation for CML: A report from the International Bone Marrow Transplant Registry
    • Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996;17 (Suppl 3):S5-S6. (Pubitemid 26181597)
    • (1996) Bone Marrow Transplantation , vol.17 , Issue.SUPPL. 3
    • Horowitz, M.M.1    Rowlings, P.A.2    Passweg, J.R.3
  • 222
    • 33646017748 scopus 로고    scopus 로고
    • Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
    • Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513-521.
    • (2006) Haematologica , vol.91 , pp. 513-521
    • Gratwohl, A.1    Brand, R.2    Apperley, J.3
  • 223
    • 77950391550 scopus 로고    scopus 로고
    • Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: Evaluation of its impact within a subgroup of the randomized German CML Study IV
    • Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010;115:1880-1885.
    • (2010) Blood , vol.115 , pp. 1880-1885
    • Saussele, S.1    Lauseker, M.2    Gratwohl, A.3
  • 224
    • 77951632041 scopus 로고    scopus 로고
    • Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase
    • Goldman JM, Majhail NS, Klein JP, et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol 2010;28:1888-1895.
    • (2010) J Clin Oncol , vol.28 , pp. 1888-1895
    • Goldman, J.M.1    Majhail, N.S.2    Klein, J.P.3
  • 225
    • 77955368678 scopus 로고    scopus 로고
    • Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I
    • Velev N, Cortes J, Champlin R, et al. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer 2010;116:3631-3637.
    • (2010) Cancer , vol.116 , pp. 3631-3637
    • Velev, N.1    Cortes, J.2    Champlin, R.3
  • 226
    • 79953689908 scopus 로고    scopus 로고
    • Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations
    • Jabbour E, Cortes J, Santos FP, et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 2011;117:3641-3647.
    • (2011) Blood , vol.117 , pp. 3641-3647
    • Jabbour, E.1    Cortes, J.2    Santos, F.P.3
  • 230
    • 0035383762 scopus 로고    scopus 로고
    • Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects
    • McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-3400.
    • (2001) Blood , vol.97 , pp. 3390-3400
    • McSweeney, P.A.1    Niederwieser, D.2    Shizuru, J.A.3
  • 232
    • 74049104918 scopus 로고    scopus 로고
    • Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era
    • Champlin R, Lima Md, Kebriaei P, et al. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 2009;9 (Suppl 3):S261-S265.
    • (2009) Clin Lymphoma Myeloma , vol.9 , Issue.SUPPL. 3
    • Champlin, R.1    Lima, Md.2    Kebriaei, P.3
  • 233
    • 0028988779 scopus 로고
    • Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome
    • Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995;85:2981-2990.
    • (1995) Blood , vol.85 , pp. 2981-2990
    • Beelen, D.W.1    Graeven, U.2    Elmaagacli, A.H.3
  • 236
    • 33646013280 scopus 로고    scopus 로고
    • The effect of prior exposure to imatinib on transplant-related mortality
    • Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006;91:452-459.
    • (2006) Haematologica , vol.91 , pp. 452-459
    • Deininger, M.1    Schleuning, M.2    Greinix, H.3
  • 237
    • 54049146732 scopus 로고    scopus 로고
    • Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
    • Lee SJ, Kukreja M, Wang T, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008;112:3500-3507.
    • (2008) Blood , vol.112 , pp. 3500-3507
    • Lee, S.J.1    Kukreja, M.2    Wang, T.3
  • 239
    • 34547178987 scopus 로고    scopus 로고
    • Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: No evidence for increased transplant-related toxicity
    • DOI 10.1002/cncr.22778
    • Jabbour E, Cortes J, Kantarjian H, et al. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 2007;110:340-344. (Pubitemid 47121894)
    • (2007) Cancer , vol.110 , Issue.2 , pp. 340-344
    • Jabbour, E.1    Cortes, J.2    Kantarjian, H.3    Giralt, S.4    Andersson, B.S.5    Giles, F.6    Shpall, E.7    Kebriaei, P.8    Champlin, R.9    De Lima, M.10
  • 240
    • 72149115289 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation (SCT) in advanced chronic myeloid leukemia (CML) patients after tyrosine kinase inhibitor (TKI) therapy
    • [abstract]. Abstract 4419
    • le Coutre PD, Hemmati P, Neuburger S, et al. Allogeneic stem cell transplantation (SCT) in advanced chronic myeloid leukemia (CML) patients after tyrosine kinase inhibitor (TKI) therapy [abstract]. Blood 2008;112:Abstract 4419.
    • (2008) Blood , vol.112
    • Le Coutre, P.D.1    Hemmati, P.2    Neuburger, S.3
  • 241
    • 58249104311 scopus 로고    scopus 로고
    • Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia
    • Shimoni A, Leiba M, Schleuning M, et al. Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia. Leukemia 2009;23:190-194.
    • (2009) Leukemia , vol.23 , pp. 190-194
    • Shimoni, A.1    Leiba, M.2    Schleuning, M.3
  • 242
    • 74849117346 scopus 로고    scopus 로고
    • Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib
    • Breccia M, Palandri F, Iori AP, et al. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res 2010;34:143-147.
    • (2010) Leuk Res , vol.34 , pp. 143-147
    • Breccia, M.1    Palandri, F.2    Iori, A.P.3
  • 243
    • 84863399997 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation for blast crisis (BC) chronic myelogenous leukemia (CML) in the tyrosine kinase inhibitors (TKIs) era. Analysis of pre-transplant variables on transplant outcome
    • On behalf of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire and the French Group of CML [abstract]. Abstract 2266
    • Nicolini F, Modolo L, Raus N, et al. Allogeneic stem cell transplantation for blast crisis (BC) chronic myelogenous leukemia (CML) in the tyrosine kinase inhibitors (TKIs) era. Analysis of pre-transplant variables on transplant outcome. On behalf of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire and the French Group of CML [abstract]. Blood 2010;116:Abstract 2266.
    • (2010) Blood , vol.116
    • Nicolini, F.1    Modolo, L.2    Raus, N.3
  • 245
    • 0026504676 scopus 로고
    • Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia
    • Roth M, Antin J, Ash R, et al. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 1992;79:276-282.
    • (1992) Blood , vol.79 , pp. 276-282
    • Roth, M.1    Antin, J.2    Ash, R.3
  • 246
    • 0025724946 scopus 로고
    • Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia
    • Delage R, Soiffer R, Dear K, Ritz J. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood 1991;78:2759-2767.
    • (1991) Blood , vol.78 , pp. 2759-2767
    • Delage, R.1    Soiffer, R.2    Dear, K.3    Ritz, J.4
  • 247
    • 0028946866 scopus 로고
    • Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients
    • Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995;85:2632-2638.
    • (1995) Blood , vol.85 , pp. 2632-2638
    • Radich, J.P.1    Gehly, G.2    Gooley, T.3
  • 248
    • 0029981482 scopus 로고    scopus 로고
    • Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia
    • Mackinnon S, Barnett L, Heller G. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1996;17:643-647. (Pubitemid 26125720)
    • (1996) Bone Marrow Transplantation , vol.17 , Issue.4 , pp. 643-647
    • Mackinnon, S.1    Barnett, L.2    Heller, G.3
  • 250
    • 0035885940 scopus 로고    scopus 로고
    • The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation
    • Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood 2001;98:1701-1707.
    • (2001) Blood , vol.98 , pp. 1701-1707
    • Radich, J.P.1    Gooley, T.2    Bryant, E.3
  • 251
    • 0029563299 scopus 로고    scopus 로고
    • Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: A comparative study
    • Costello RT, Kirk J, Gabert J. Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study. Leuk Lymphoma 1996;20:239-243. (Pubitemid 126714875)
    • (1996) Leukemia and Lymphoma , vol.20 , Issue.3-4 , pp. 239-243
    • Costello, R.T.1    Kirk, J.2    Gabert, J.3
  • 253
    • 0029100438 scopus 로고
    • Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
    • Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-2050.
    • (1995) Blood , vol.86 , pp. 2041-2050
    • Kolb, H.J.1    Schattenberg, A.2    Goldman, J.M.3
  • 254
    • 0036240028 scopus 로고    scopus 로고
    • Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation
    • Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002;9:123-137. (Pubitemid 34457331)
    • (2002) Cancer Control , vol.9 , Issue.2 , pp. 123-137
    • Luznik, L.1    Fuchs, E.J.2
  • 255
    • 0037236630 scopus 로고    scopus 로고
    • Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia
    • DOI 10.1080/1042819021000050061
    • Gilleece MH, Dazzi F. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk Lymphoma 2003;44:23-28. (Pubitemid 36113826)
    • (2003) Leukemia and Lymphoma , vol.44 , Issue.1 , pp. 23-28
    • Gilleece, M.H.1    Dazzi, F.2
  • 258
    • 10344241010 scopus 로고    scopus 로고
    • Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation
    • Anderlini P, Sheth Sl, Hicks K, et al. Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant 2004;10:883-884.
    • (2004) Biol Blood Marrow Transplant , vol.10 , pp. 883-884
    • Anderlini, P.1    Sl, S.2    Hicks, K.3
  • 259
    • 19244365177 scopus 로고    scopus 로고
    • Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: Durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease
    • DOI 10.1158/1078-0432.CCR-03-0580
    • DeAngelo DJ, Hochberg EP, Alyea EP, et al. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004;10:5065-5071. (Pubitemid 39099780)
    • (2004) Clinical Cancer Research , vol.10 , Issue.15 , pp. 5065-5071
    • DeAngelo, D.J.1    Hochberg, E.P.2    Alyea, E.P.3    Longtine, J.4    Lee, S.5    Galinsky, I.6    Parekkedon, B.7    Ritz, J.8    Antin, J.H.9    Stone, R.M.10    Soiffer, R.J.11
  • 261
    • 33947587233 scopus 로고    scopus 로고
    • Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia
    • DOI 10.1182/blood-2006-04-019836
    • Carpenter PA, Snyder DS, Flowers MED, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007;109:2791-2793. (Pubitemid 46482072)
    • (2007) Blood , vol.109 , Issue.7 , pp. 2791-2793
    • Carpenter, P.A.1    Snyder, D.S.2    Flowers, M.E.D.3    Sanders, J.E.4    Gooley, T.A.5    Martin, P.J.6    Appelbaum, F.R.7    Radich, J.P.8
  • 262
    • 33744503915 scopus 로고    scopus 로고
    • A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation
    • Weisser M, Tischer J, Schnittger S, et al. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006;91:663-666. (Pubitemid 43799465)
    • (2006) Haematologica , vol.91 , Issue.5 , pp. 663-666
    • Weisser, M.1    Tischer, J.2    Schnittger, S.3    Schoch, C.4    Ledderose, G.5    Kolb, H.J.6
  • 263
    • 51649111035 scopus 로고    scopus 로고
    • Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
    • Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112:1005-1012.
    • (2008) Blood , vol.112 , pp. 1005-1012
    • Porkka, K.1    Koskenvesa, P.2    Lundan, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.